Results 81 to 90 of about 187,458 (237)

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing N6‐Methyladenosine Methylation of Myc

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Ibrutinib resistance remains a major obstacle in the treatment of diffuse large B‐cell lymphoma (DLBCL). Fat mass and obesity‐associated protein (FTO) has been implicated in drug resistance through its regulation of N6‐methyladenosine (m6A) modifications; however, whether FTO mediates ibrutinib resistance in DLBCL remains unclear.
Ting‐Ting Lu, Jin‐Hao Chen, Yan‐Fang Wang, Xiao Wu, Hui‐Yun Ni, Qiu‐Rong Zhang   +5 more
wiley   +1 more source

Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model [PDF]

, 2014
X-linked agammaglobulinemia (XLA) is an inherited immunodeficiency that results from mutations within the gene encoding Bruton’s tyrosine kinase (BTK). Many XLA-associated mutations affect splicing of BTK pre-mRNA and severely impair B cell development ...
Behlke, Mark A, Berglöf, Anna, Bestas, Burcu, Blomberg, K Emelie M, El Andaloussi, Samir, Gait, Michael J, Gustafsson, Manuela O, Guterstam, Peter, Kharazi, Shabnam, Lundin, Karin E, Mohammad, Dara K, Moreno, Pedro M D, Månsson, Robert, Nordin, Joel Z, Piątosa, Barbara, Roberts, Thomas C, Saleh, Amer F, Smith, C I Edvard, Sutlu, Tolga, Wengel, Jesper, Wood, Matthew J A   +20 more
core   +1 more source

Sequence of Immunological Events During IgE‐Mediated Allergic Reactions to Food

Allergy, EarlyView.
ABSTRACT Food allergies (FA) represent a significant global health burden. Upon allergen re‐exposure, allergic patients exhibit a sequence of symptoms that vary in terms of affected organ systems, severity, time of onset and allergen reactivity thresholds.
N. A. Nagy, D. Schnoegl, V. Houghton, L. O'Mahony, A. F. Santos, E. F. Knol, A. Kuehn, T. Eiwegger   +7 more
wiley   +1 more source

Bruton's tyrosine kinase inhibition for the treatment of allergic disorders. [PDF]

Ann Allergy Asthma Immunol
Lin EV, Suresh RV, Dispenza MC.
europepmc   +2 more sources

Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production. [PDF]

, 1998
We investigated the role of Bruton's tyrosine kinase (Btk) in FcepsilonRI-dependent activation of mouse mast cells, using xid and btk null mutant mice.
Alt, FW, Galli, SJ, Goldfeld, AE, Han, W, Hartman, SE, Hata, D, Inagaki, N, Kawakami, T, Kawakami, Y, Khan, WN, Kitamura, T, Lantz, CS, Maeda-Yamamoto, M, Miura, T, Nagai, H, Witte, ON, Yao, L   +16 more
core  

Unmet Needs in Treatment Escalation for Chronic Spontaneous Urticaria: Findings From the CURE Registry

Allergy, EarlyView.
Appropriate treatment escalation improves CSU disease control. However, only about a quarter of patients achieve a complete response, the main goal of CSU treatment. Approximately one‐third of patients clinically eligible for escalation (UCT < 12) do not receive guideline‐recommended treatment escalation and remain symptomatic on their current ...
Pavel Kolkhir, Pascale Salameh, Magdalena Zajac, Alicja Kasperska‐Zajac, Ana Giménez‐Arnau, Maria Puertolas, Hanna Bonnekoh, Carolina Vera Ayala, Michael Makris, Eleni Chatzidimitriou, Stamatios Gregoriou, Kanokvalai Kulthanan, Andrea Bauer, Mojca Bizjak‐Suran, Daria Fomina, Alexis Bocquet, Joachim Dissemond, Mohamed Abuzakouk, Tara Raftery, Nadine Chapman‐Rothe, Emek Kocatürk, Clive Grattan, Riccardo Asero, Jonny G. Peter, Simon Francis Thomsen, Karsten Weller   +25 more
wiley   +1 more source

Targeting Solid Tumors With BTK Inhibitors

Frontiers in Cell and Developmental Biology, 2021
The repurposing of FDA-approved Bruton’s tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemotherapy-resistant cancer patients.
Fatih M. Uckun, Taracad Venkatachalam
doaj   +1 more source

Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor [PDF]

, 2014
A number of Bruton's tyrosine kinase (BTK) inhibitors are currently in development, yet it has been difficult to visualize BTK expression and pharmacological inhibition in vivo in real time.
Kim, Eunha, Kohler, Rainer H., Miller, Miles A., Turetsky, Anna, Weissleder, Ralph   +4 more
core   +1 more source

Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation

Current Oncology Reports, 2021
The purpose of this review is to summarize the epidemiology, mechanisms, and management of cardiovascular complications of Bruton’s Tyrosine Kinase inhibitors (BTKIs).
M. Sestier, C. Hillis, G. Fraser, D. Leong   +3 more
semanticscholar   +1 more source